

A Partnership Including  
Professional Corporations  
600 13th Street, N.W.  
Washington, D.C. 20005-3096  
202-756-8000  
Facsimile 202-756-8087  
<http://www.mwe.com>

2636 03 MAY 20 09:07

Boston  
Chicago  
London  
Los Angeles  
Miami  
Moscow  
New York  
Orange County  
St. Petersburg  
Silicon Valley  
Vilnius  
Washington, D.C.

**MCDERMOTT, WILL & EMERY**

May 19, 2003

**VIA FEDERAL EXPRESS**

Dockets Management Branch  
Food and Drug Administration  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061, HFA-305  
Rockville, MD 20852

Re: Notice of QT5, Inc.'s Intent to File Comments  
Concerning Citizen Petition - Docket No. 01P-0572  
and Supplemental Citizen Petition - Docket No. 01P-0573

Dear Sir/Madam:

I am writing on behalf of our client QT5, Inc. with respect to the above referenced Citizen Petition and Supplemental Citizen Petition. In conjunction with the company, outside homeopathic pharmaceutical experts and counsel, we have evaluated the above referenced Citizen Petition and Supplement concerning QT5, Inc.'s homeopathic drug product containing Nicotinum, NICOWater™ and are in the process of preparing formal comments for submission to the docket. These formal comments will demonstrate and support the conclusion that the Citizen Petition and Supplemental Citizen Petition are without merit and should therefore be denied. Accordingly, we trust that the Agency will not take any action or issue a response to the Petitioners until such comments are received.

We will submit substantive comments on the Citizen Petition and Supplemental Citizen Petition within the next 30 days.

Sincerely yours,



David L. Rosen, R.Ph., J.D.

cc: QT5, Inc.  
Mr. Steve Reder

Michael Landa, Esq.  
FDA, Office of the Chief Counsel

**OIP-0572**

**LET 3**